Objective: Create a brief, self-report screener for recently diagnosed breast cancer patients to identify patients at risk of future depression.
| INTRODUCTION
Prevention and treatment of depression are vital for optimal cancer survivorship. In breast cancer patients, the prevalence of depressive disorders triples during breast cancer treatment, as compared to demographically similar community women, and mortality risk increases 1 via mechanisms that are beginning to be understood. 2 Persistent depressive symptoms and major depressive episodes (MDEs) in breast cancer survivors are linked to poor medical regimen adherence and unhealthy behaviors 3, 4 delayed return to work, 5 higher healthcare use, costs and depression-associated hospitalizations, 6 as well as increased suicide. 7 Although valid methods for identification and treatment of cancer patients with current depressive disorders are available, 8, 9 there are no clinically practical approaches to screening for risk of future depression to facilitate preventive interventions. Walker et al 10 demonstrated that screening followed by treatment of cancer patients with MDE is feasible and cost effective, setting the stage for a parallel effort to detect and intervene with patients at elevated risk to prevent depressive disorders.
The objective of this project was to use data from a longitudinal study of breast cancer patients to create a brief, self-report prognostic screener for depression [Depression Risk Questionnaire (DRQ)] that is feasible for clinical practice.
| METHODS
This project is a component of the My Year After (MYA) breast cancer study, a prospective, longitudinal investigation of a theory 17 and evidence based 15, 18 Figure 1 shows participant flow. oped an MDE and 38% were estimated to have chronically elevated depressive symptoms over 16 months after diagnosis. 22 
| Depression outcome

| Candidate items
Eight categories of risk for depression ( Figure 1A -H) were assessed using 42 self-report scales plus descriptive characteristics (219 items):
(1) general depressive diatheses (history of depression, neuroticism, early adversity, loneliness, and marital dysfunction), (2) emotion dysregulation diatheses (emotion acceptance, emotion regulation, suppression, reappraisal, and attachment security), (3) coping (emotion expression and processing, seeking support, acceptance, behavioral and mental disengagement, denial, and problem solving), (4) noncancer stressors, (5) cancer severity and treatments (multiple items), (6) physical health problems (neuropathy, insomnia, pain, fatigue, number of comorbid diseases, and other breast cancer adverse effects), (7) psychological health (depression/anxiety symptoms, intrusive thoughts, positive emotions, substance abuse, satisfaction with life), and (8) demographics. 22 Measures for each risk characteristic are in SDC Sections A and C and SDC Table 1 .
| Statistical methods
We used high-performance prediction modeling to identify a small set of items that were highly predictive of the depression outcomes.
Model development and validation are summarized here, with details in SDC Section B. Missing data were multiply imputed using bagged trees 29 to generate 25 imputed datasets separately for the development and validation samples. All performance metrics and tests were conducted on the multiply imputed data. Pooled results are reported.
Multiple imputation and prediction models were conducted using the R packages caret 30 and gbm. 31 
| Development
The prediction model was created on the development sample using stochastic gradient boosting of classification trees ("GBM"). GBM is a machine learning technique that produces a prediction model as an ensemble of many classification and regression trees, iteratively trained; cases misclassified at 1 iteration are given greater weight during later iterations. 32, 33 See Adams et al 34 for an example of predictive modeling.
A detailed description of the analytic steps to select the best set of items for the screener can be found in SDC Section B. Briefly, after optimizing the tuning parameters to get the best fitting model, the were used to select the smallest number of items without substantial loss of performance. After the final number of items was selected,
we fit a logistic model ("GLM") using these items to develop a simple summation scoring method suitable for a brief screener.
To classify individuals as high or low risk for the depression outcome, we selected a threshold of PPV ≈ 0.80 a priori consistent with our goal of developing a prognostic screener in order to allocate potentially limited intervention resources effectively (ie, if a woman screens positive, she has a high probability of it being a true positive). For the GBM and GLM, we used predicted probability thresholds and for the brief screener we used integer-valued thresholds corresponding to PPVs of 0.80. Performance metrics were calculated for the development sample using these thresholds. McNemar tests were conducted to assess whether the methods classified the same women differently.
| Validation
The models and thresholds derived from the development process were applied to the holdout validation sample to evaluate performance.
| Results
The mean age of subjects was 56 (±12) years. Nineteen percent were Latina, 5% Asian, 2% each African American and American Indian, and the rest European American Caucasian. Most had some college education (75%), were married (67%), and employed (52%). Most had early-stage breast cancer (stages 1, 2, 3, and 4: 44%, 39%, 11%, and with NEO) was substituted in the DRQ-7 for copyright purposes. 5%, respectively) and surgery, chemotherapy, and endocrine therapy during the study. 22 Women in the development and validation samples were not significantly different on demographic characteristics. In the development (validation) samples, 17% (17%) experienced an MDD, 47% (41%) were in the high trajectory class, and 51% (41%) experienced 1 or both of these depression outcomes (SDC Table 2 ). Mean CES-D scores were 17.6 ± 7.3 for women with depression outcomes and 5.1 ± 3.4 for the others (SDC Figure 3) .
| Development
Gradient boosting modeling (GBM) yielded a ranking of items by their importance for predicting the depression outcome. Using the top 7
items for the DRQ-7 balanced near optimal performance with brevity, as ascertained by varying the number of top-performing items used for prediction and calculating performance measures. SDC Figure 4 shows improvement in prediction with each additional item up to 7 and then no substantial improvement when adding items up to a total of 30 and beyond. Table 1 lists the coefficients for weighted scoring of the sum of these items. Table 2 shows how the original item scorings were harmonized and simplified to create the DRQ-7 screener, with further explanation of item scoring in SDC Section C. Table 3A shows model performance including threshold, C-statistic, accuracy, kappa, sensitivity, specificity, PPV, and NPV for both scales. McNemar tests showed significantly different classification with the DRQ-7 and the PHQ-4 (P = .005). Results for thresholds achieving maximum accuracy favored the DRQ-7.
Model performance in the development sample was reexamined excluding women with PHQ-9 ≥ 10 at study entry (n = 59). Although sensitivity was reduced, overall the model still performed well with C-statistic of 0.80, accuracy 0.75, sensitivity 0.66, and specificity 0.81.
| Validation
The developed screening models and thresholds were applied to the validation sample (N = 82). Performance metrics are shown in Table 4 (SDC Table 4A shows performance for additional models, SDC Table   4B shows performance using thresholds maximizing accuracy and SDC Table 4C 
| Post hoc analyses-net reclassification improvement
Comparisons of the DRQ-7 with the PHQ-4 to classify women on depression outcomes for the full sample were calculated with bootstrapped 95% confidence intervals using the net reclassification improvement (NRI) index. The NRI 35 quantifies the total improvement in the classification of depression outcomes when the 4 items of the DRQ-7 are added to items from the PHQ-4 contained within the DRQ-7.
NRI favored the DRQ-7 over the PHQ-4 for the sample overall Table 5 . 
| Selection of thresholds
Although we used a threshold sum score of 6 for the DRQ-7, depending on the desired sensitivity and specificity, alternate thresholds may be used. Figure The DRQ-7 items that quantify symptoms of depressed mood, anhedonia and worry are known to be malleable with available interventions. 37 The items measuring loneliness, persistent sadness, and acceptance of emotions quantify vulnerabilities that are thought to be more enduring; however, recent interventions suggest they are malleable, 38 and variation in depression vulnerability over time in recent cohort studies supports this view. 15 Thus, risk processes tapped by the DRQ-7 show promise as targets for preventive interventions.
To our knowledge, the only published trial of selective or indicated preventive intervention for MDD in cancer patients studied a brief nurse-delivered intervention that reduced the incidence of MDD among high-risk patients (previous mental health treatment or ≥8/56 cancer-related concerns score) compared to wait-list controls. The intervention had no significant impact among low-risk subjects. 39 This demonstrates the value of a screener to identify individuals at significant risk as the targets for preventive interventions.
| Limitations and strengths
The DRQ-7 is not a purely predictive screener, as we did not exclude women with elevated symptoms or MDD at study entry from the sample. Four subjects met criteria for MDE at study enrollment, and they were also in the high trajectory group throughout the next 12 months. Our pragmatic aim was to produce a prognostic screener for use in the first few months after breast cancer diagnosis (near the usual onset of adjuvant therapy), and exclusion of these subjects would have eliminated part of the high-risk group. Clinical settings aiming to separate subjects with current depressive disorders from those at risk for depression in the next year could administer the DRQ-7 or the PHQ-4 and score the PHQ-2 items (included in the DRQ-7 and the PHQ-4) using established thresholds for current MDD. 40 Participants were recruited from 2 geographic areas to increase heterogeneity; however, the findings may not generalize to all recently diagnosed breast cancer patients, and its use in men and for patients with other types of cancer awaits study. Although we made efficient use of the sample to cross-validate the DRQ-7, the sample size was limited due to time and cost constraints. Validation should be considered preliminary pending a larger validation study. The study also had notable strengths. We used a theoretically and empirically grounded framework to comprehensively assess risk and protective factors for depression in women with breast cancer. We used one of the strongest study designs (type 2b) according to the TRIPOD statement, making a nonrandom split of the sample to provide preliminary evidence that the DRQ-7 performs well in data not used for development and generalizes across time. 19 
| Clinical implications
Prospective studies of risk for depression after breast cancer diagnosis have established a strong evidence base for individual risk indicators.
However, this knowledge has not been translated to produce an efficient and accurate screener to identify the subset of women who are most likely to benefit from preventive interventions. These results indicate that the DRQ-7 and the PHQ-4 warrant further study for this task. Which scale to use in an individual clinic may be informed by the pragmatics of current practice and the perceived importance of 10% increased classification accuracy with the DRQ-7 vs. the PHQ-4.
| Conclusions
Accurate identification of individuals at risk can maximize the benefits of limited therapeutic resources. The DRQ-7 and a new PHQ-4 cutoff score were developed as practical tools to identify patients at risk for clinically significant depression in the year after breast cancer diagnosis. They compare favorably with PredictD, a well-validated algorithm for stratifying primary care patients for depression risk over 24 months.
Validation in a larger sample, and in other cancer types, will set the stage for selecting and targeting patients for interventions to prevent depression after cancer diagnosis. 
